by Marina Chenery | Jun 20, 2022 | News
Optibrium receives further investment from Kester Capital Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology. CAMBRIDGE, UK, 21 June 2022 – Optibrium™, a developer of...
by Marina Chenery | Jun 9, 2022 | StarDrop Tutorials, Tutorials
Inspyra This worked example uses Inspyra™ to interactively explore optimisation strategies to achieve a selective inhibitor of DPP-4 with appropriate physicochemical properties. Starting from a data set of compounds representing three chemical series based on...
by Marina Chenery | Jun 9, 2022 | StarDrop Tutorials, Tutorials
In this worked example, we will explore ways to use the Inspyra Panel, in combination with Matched Series Analysis (MSA). MSA goes beyond Matched Pair Analysis and uses longer series of matched compounds to propose new substitutions that are likely to improve activity...
by Marina Chenery | Jun 8, 2022 | Webinars
Perfecting the use of imperfect QSAR models In this webinar, we examine the effective use of QSAR modelling in drug discovery and discuss a variety of pain points for medicinal chemists in knowing when a model can be trusted and how to avoid common pitfalls. We...
by Marina Chenery | Jun 8, 2022 | News
Optibrium expands UK head office with new facilities on Cambridge Innovation Park Investment in new headquarters forms part of ongoing company growth plans. The new facility supports the continued success of Optibrium’s drug discovery technologies and...